Antibody cocktail effective against variants of SARS-CoV-2

Código QR

Antibody cocktail effective against variants of SARS-CoV-2

Abstract Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutral...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu-Chi Chou, Ruei-Min Lu, Hsiu-Ting Lin, Wan-Yu Chen, Yi-Ling Lin, Mi-Hua Tao, Jia-Tsrong Jan, Han-Chung Wu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Receptor-binding domain (RBD) Neutralizing antibody Cocktail therapy Medicine R
Acceso en línea:	https://doaj.org/article/7e765143995640ccb0b25900e804ab12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations
por: Damiano Buratto, et al.
Publicado: (2021)

Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding
por: James R. Byrnes, et al.
Publicado: (2020)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <italic toggle="yes">In Vivo</italic> in a Mouse Model in a Neutralization-Dependent Manner
por: Fatima Amanat, et al.
Publicado: (2021)

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
por: Gururaj Rao Deshpande, et al.
Publicado: (2021)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Su-Jin Park, et al.
Publicado: (2020)

Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19
por: Tarlan Mamedov, et al.
Publicado: (2021)

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
por: Guillaume Beaudoin-Bussières, et al.
Publicado: (2020)

Guillain-Barré Syndrome Associated with COVID-19 Vaccination
por: Shih-Chieh Shao, et al.
Publicado: (2021)

Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine
por: Taweewun Hunsawong, et al.
Publicado: (2021)

Surface‒Aerosol Stability and Pathogenicity of Diverse Middle East Respiratory Syndrome Coronavirus Strains, 2012‒2018
por: Neeltje van Doremalen, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Lin Yang, et al.
Publicado: (2021)

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
por: Vimvara Vacharathit, et al.
Publicado: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
por: Chin-Shern Lau, et al.
Publicado: (2021)

Seroprevalence of Severe Acute Respiratory Syndrome-Coronavirus-2 Immunoglobulin M and Immunoglobulin G Antibodies among the Population of Koya University
por: Safia S. I. Blbas, et al.
Publicado: (2021)

Clinical and Epidemiological Characteristics of 1283 Pediatric Patients with Coronavirus Disease 2019 during the First and Second Waves of the Pandemic—Results of the Pediatric Part of a Multicenter Polish Register SARSTer
por: Maria Pokorska-Śpiewak, et al.
Publicado: (2021)

Real-Time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA
por: Kaitlyn E. Johnson, et al.
Publicado: (2021)

Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May–August 2020
por: Maximilian Stich, et al.
Publicado: (2021)

SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, Liberia, 2021
por: Bode Shobayo, et al.
Publicado: (2021)

SARS-CoV-2 Variants, South Sudan, January–March 2021
por: Daniel Lule Bugembe, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 Variant Infection in Malayan Tigers, Virginia, USA
por: Patrick K. Mitchell, et al.
Publicado: (2021)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Andreina Baj, et al.
Publicado: (2021)

Detection of SARS-CoV-2 in Wastewater at Residential College, Maine, USA, August–November 2020
por: Yolanda M. Brooks, et al.
Publicado: (2021)

SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021
por: Jackie Kleynhans, et al.
Publicado: (2021)

Clinical characteristics of asymptomatic carriers of novel coronavirus disease 2019: A multi-center study in Jiangsu Province
por: Jiaxin Chen, et al.
Publicado: (2020)

New Clinical Anatomical Interpretation of COVID-19 Pandemic Infection
por: Al-Dorazi,Shorok, et al.
Publicado: (2021)

Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential
por: Slawomir Kubik, et al.
Publicado: (2021)

Modern Epidemics: From the Spanish Flu to COVID-19
por: Megan A. Greischar
Publicado: (2021)

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
por: Jin Wang, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development
por: Kabeer Haneef, et al.
Publicado: (2021)

Challenges in managing children with Autism Spectrum Disorder and COVID-19: A case report
por: Shaji George, et al.
Publicado: (2021)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Frank-Peter Tillmann, et al.
Publicado: (2021)

Safety and Efficacy of the East Coast Fever Muguga Cocktail Vaccine: A Systematic Review
por: Fiona K. Allan, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Constant Gillot, et al.
Publicado: (2021)

Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
por: Kim J. Hasenkrug, et al.
Publicado: (2021)

An Arab Adolescent with Multisystem Inflammatory Syndrome Associated with COVID-19: A Report from Syria
por: Jaafer Zaino, et al.
Publicado: (2021)

Routine SARS-CoV-2 RT-PCR testing before digestive endoscopy during the peak of the pandemic - a single tertiary center experience
por: Karolina Novakova, et al.
Publicado: (2021)

Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection <italic toggle="yes">In Vitro</italic>
por: Francesca Curreli, et al.
Publicado: (2020)

<italic toggle="yes">In Silico</italic> Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
por: Nishant Shekhar, et al.
Publicado: (2020)

The immune response to the novel coronavirus infection
por: Vyacheslav S. Fedorov, et al.
Publicado: (2021)

Antibody Responses to SARS-CoV-2 Infection—Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA
por: Dinesh Mohanraj, et al.
Publicado: (2021)